

Alex J. Mayer, PhD, MS, PMP
Cabinet Secretary

Christy D. Donohue, CMC
Commissioner

**West Virginia Medicaid Drug Utilization Review Board Minutes
02.25.2026**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
Scott Brown, RPh
Phillip Galapon, MD
Lester Labus, MD
Michael Lonsinger, PharmD
Kate Forman, PharmD
Michael Ballow, PharmD
Ernest Miller, DO

Members Absent:

David Gloss, MD, Vice Chair
C.K. Babcock, PharmD
Chris Booth, PharmD
Mary Nemeth-Pyles, MSN, RN, CS

Department of Human Services (DoHS)/Bureau for Medical Services (BMS) Staff:

Gail Goodnight, PharmD
Lori Moles, PharmD
William Hopkins, PharmD, Pharmacy Operations Manager
Kristen Boustany, PharmD, Director of Pharmacy Services
Kevin McCann, WV Medicaid Medical Director
Priya Shah, PharmD, Drug Utilization Review Coordinator

Other Contract/State Staff Present:

Joe Bergondo, PharmD – Change Healthcare
Roberta Capp, MD – Optum Rx
Eric Sears, RPh – Gainwell Technologies
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP) Director
Christopher Hale, PharmD – Rational Drug Therapy Program (RDTP) Director
Scott Donald, PharmD – Acentra Health Director of Clinical Services
Rachele Poissant, PharmD -- Acentra Health Clinical Account Manager
Cory Chambliss -- Acentra Health Operations Director

1. **INTRODUCTIONS**

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:00 PM (EST). The DUR Board and others introduced themselves.

2. **APPROVAL OF MINUTES FROM November 19, 2025 DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion



3. **OLD BUSINESS**
 - a. None

4. **NEW BUSINESS**
 - a. **Speakers**
 - i. None
 - b. **Updates from January 28, 2026 Pharmaceutical & Therapeutics (P&T) Committee Meeting**
 - i. Dr. Joe Bergondo presented the PDL status updates from the January 28, 2026 P&T meeting.
 - c. **Prior Authorization Criteria.** Attachment A
 - i. **Rhapsido**, approved as written
 - ii. **Tonmya**, approved as written
 - iii. **Hereditary Angioedema agents (acute)**, approved as written
 - iv. **Hereditary Angioedema agents (prophylaxis)**, approved as written
 - v. **Vyscoxa**, approved as written

5. **REPORTS—4th QUARTER 2025**
 - a. **Gainwell Technologies Quarterly Report:** Mr. Eric Sears presented an overview of the 2025 Fourth Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the Fourth Quarter of 2025. Attachment C.
 - c. **Acentra Health:** Dr. Rachele Poissant presented a summary of the RDUR interventions for the Fourth Quarter of 2025. Attachment D.

6. **OTHER BUSINESS**
 - a. None

7. **NEXT MEETING AND ADJOURNMENT**
 - a. The meeting concluded at 5:11 PM (EST). The next meeting will be May 27th, 2026.

